Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.80
+0.02710.08%
Post-market: 33.77-0.0271-0.08%16:10 EDT
Volume:222
Turnover:8K
Market Cap:13.52M
PE:- -
High:33.80
Open:33.77
Low:33.80
Close:33.77
52wk High:34.98
52wk Low:27.25
Shares:400.00K
Float Shares:400.00K
Volume Ratio:0.14
T/O Rate:0.06%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Yahong Meditech's APL-2501 Doses First Patient in Phase I Study for Advanced Solid Tumors

Stock News
·
Sep 22

Hong Kong Stock Flash | JW (Cayman) Therapeutics (02126) Surges Over 20% Intraday as CAR-T Therapy Makes Historic Debut in Basic Medical Insurance Negotiations

Stock News
·
Sep 22

Insight Molecular Diagnostics Revises Chronix Royalty Agreement Terms

TIPRANKS
·
Sep 22

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22

Estee Lauder Cos. Cl a Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22

Moderna Inc. Stock Climbs 12.3%, Outperforms Peers

Dow Jones
·
Sep 22

Nvidia Corp., Merck Share Gains Lead Dow's 425-Point Climb

Dow Jones
·
Sep 22

J&J says Caplyta Phase 3 study in bipolar I met primary endpoint

TIPRANKS
·
Sep 21

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 21

Avalyn Pharma announces published results from Phase 1 trials of AP02

TIPRANKS
·
Sep 21

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

GlobeNewswire
·
Sep 21

Johnson & Johnson Says Phase 3 Trial Shows Caplyta Cuts Bipolar I Mania Symptoms by Week 3

Reuters
·
Sep 21

J&J - Caplyta Demonstrates Statistically Significant Rapid Reduction in Manic Symptoms at Week 3

THOMSON REUTERS
·
Sep 21

Caplyta® (Lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Pivotal Phase 3 Study

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Well-Tolerated; Dry Mouth and Nausea Most Common Adverse Events

THOMSON REUTERS
·
Sep 21

LIVE Markets-Big Beauty Faces Growing Threat from AI, Smaller Rivals

Reuters
·
Sep 21

Japan Health Ministry Approves Merck’s Keytruda QLEX for Subcutaneous Use Across Keytruda Indications

Reuters
·
Sep 21

Merck’s Keytruda Qlex™ (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Approved in Japan for Subcutaneous Administration for All Keytruda® (Pembrolizumab) Indications Approved in Japan

THOMSON REUTERS
·
Sep 21

Ultragenyx price target raised to $35 from $32 at Barclays

TIPRANKS
·
Sep 21

Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approval for SHR-4595 Injection

Stock News
·
Sep 21